Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
Avalo Therapeutics reported a clinical milestone: it has completed enrollment in its Phase 2 LOTUS Trial evaluating AVTX-009 for hidradenitis suppurativa. The company disclosed the update via a press release furnished as Exhibit 99.1 to this report, dated October 29, 2025. This marks the transition from recruitment to data collection and analysis for the study.
Avalo Therapeutics, Inc. filed a current report to note that on October 10, 2025 it posted an updated investor presentation on its website. This presentation, attached as Exhibit 99.1, is intended for use from time to time in meetings with investors and is incorporated into the report by reference.
The filing does not describe new financial results or major transactions, but formally makes the investor presentation part of Avalo’s public disclosure record for shareholders and analysts who follow the company.
Avalo Therapeutics insider stock option grant to Chief Business Officer — Boyd Taylor received a stock option on 10/01/2025
The option covers 275,000 shares of common stock with an exercise price of $12.96 and an expiration date of 10/01/2035. The award vests over four years: 25% vests on the first anniversary of the grant and the remainder vests in equal monthly installments over the next three years, subject to continued employment. Following the grant the reporting person beneficially owns 275,000 shares directly.
Boyd Taylor, identified as Chief Business Officer and a director, filed an initial Form 3 for Avalo Therapeutics, Inc. (AVTX) reporting the event date 10/01/2025. The filing states no securities are beneficially owned by the reporting person. The form was signed under power of attorney by Donald R. Reynolds on 10/06/2025. The submission confirms an initial disclosure with no ownership to report.
Avalo Therapeutics director Kevin Robert Lind was granted a stock option on 10/01/2025 to buy 40,200 shares of common stock at an exercise price of $12.96. The option becomes exercisable in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to the director's continued service. The option expires on 10/01/2035 and the reporting Form 4 was filed on 10/02/2025 by power of attorney. The grant is reported as a direct holding and shows 40,200 shares underlying the derivative security following the transaction.
Avalo Therapeutics, Inc. (AVTX) director Kevin Robert Lind filed an initial Form 3 reporting that he does not beneficially own any securities of the issuer. The Form 3 lists the qualifying event date as 10/01/2025 and is signed by Donald R. Reynolds by power of attorney on 10/02/2025. The filing gives the reporter's address as 1500 Liberty Ridge Drive, Suite 321, Wayne, PA 19087.
Rita Jain, a director of Avalo Therapeutics, Inc. (AVTX), reported a grant of stock options on 09/30/2025. The filing shows the grant of 1,572 stock options with an exercise price of $12.71. The options were reported as 100% vested in the explanatory note. The options are linked to 1,572 underlying shares and are held directly by Ms. Jain following the transaction. The derivative table lists an expiration or related date of 09/30/2035, and the reported transaction was signed by a power of attorney on 10/02/2025.
Avalo Therapeutics, Inc. reported the appointment of Taylor Boyd as Chief Business Officer, effective October 1, 2025. Boyd brings nearly 15 years of experience in biotech business development, corporate finance, and investment banking, including senior roles at Abzena and Longboard Pharmaceuticals, where he led significant M&A and licensing activity.
Under an employment agreement dated September 29, 2025, Boyd will receive a base salary of $465,000 and a discretionary annual bonus targeted at up to 40% of base salary, payable in cash or, if mutually agreed, immediately vested equity. As an inducement, he will be granted a stock option for 275,000 shares of Avalo common stock on October 1, 2025, with an exercise price equal to the Nasdaq closing price on the grant date and vesting over four years.
If Avalo terminates Boyd without Cause or he resigns for Good Reason, severance protections include continued salary for nine months (extended to 12 months if termination occurs within six months after a Change in Control), a prorated or enhanced bonus depending on timing, full vesting of outstanding options with six months to exercise, and up to 12 months of COBRA premium payments, all conditioned on a release of claims and compliance with confidentiality, non-disparagement, invention assignment, non-competition, and non-solicitation covenants.
Avalo Therapeutics, Inc. reported changes to its board of directors. The company’s board appointed Kevin Lind as a director effective October 1, 2025, and he will also join the Audit Committee, serving until the 2026 annual meeting or until a successor is elected and qualified.
In line with Avalo’s Amended and Restated Non-Employee Director Compensation Plan, Mr. Lind will receive a non-qualified stock option to purchase 40,200 shares of common stock on October 1, 2025, vesting in three equal annual installments, with an exercise price equal to that day’s Nasdaq Capital Market closing price.
June Almenoff, M.D., Ph.D. resigned as a director, effective October 1, 2025, to pursue new opportunities; her resignation, including from the Audit Committee, is stated as not related to the company’s operations, policies, or practices. Avalo is accelerating vesting of her outstanding equity awards as of October 1, 2025, and extending the expiration dates of her outstanding stock options to September 30, 2026.
Patrick J. Crutcher filed an amended Schedule 13G reporting beneficial ownership of 549,467 shares of Avalo Therapeutics, Inc. common stock, representing 4.2% of the 13,152,356 shares outstanding cited from the issuer's August 7, 2025 prospectus. The filing shows the Reporting Person holds sole voting and dispositive power over all reported shares and indicates the position is not held to change or influence control of the company. The filing includes the Reporting Person's address in Atlanta, GA, and a certification that the securities were not acquired in connection with any control transaction.